Publications by authors named "Geoffrey A Kerchner"

Claim this Profile
S
Synergistic effects of ε4 and Alzheimer's pathology on the neural correlates of episodic remembering in cognitively unimpaired older adults.
Alexandra N Trelle, Jintao Sheng, Edward N Wilson, America Romero, Jennifer Park, Geoffrey A Kerchner

bioRxiv· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial.
Randall J Bateman, Yan Li, Eric M McDade, Jorge J Llibre-Guerra, David B Clifford, Geoffrey A Kerchner

Lancet Neurol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Parkinson's disease is characterized by vitamin B6-dependent inflammatory kynurenine pathway dysfunction.
Edward N Wilson, Jacob Umans, Michelle S Swarovski, Paras S Minhas, Justin H Mendiola, Geoffrey A Kerchner

NPJ Parkinsons Dis· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma Aβ/Aβ is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer's disease spectrum.
Alexandra N Trelle, Christina B Young, Hillary Vossler, Javier Ramos Benitez, Karly A Cody, Geoffrey A Kerchner

Alzheimers Dement· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD).
Mercè Boada, Anuja Neve, Bibha Das, Jakub Wojtowicz, Zhiyue Huang, Geoffrey A Kerchner

J Alzheimers Dis· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial.
Randall J Bateman, Yan Li, Eric M McDade, Jorge J Llibre-Guerra, David B Clifford, Geoffrey A Kerchner

medRxiv· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial.
Gennaro Pagano, Annabelle Monnet, Adriana Reyes, Benjamin Ribba, Hanno Svoboda, Geoffrey A Kerchner

Nat Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biologically defined neuronal synuclein disease as a tool to advance drug development.
Gennaro Pagano, Tien Dam, Geoffrey A Kerchner, Wendy R Galpern, Milton Biagioni

NPJ Parkinsons Dis· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma pTau181 Reveals a Pathological Signature that Predicts Cognitive Outcomes in Lewy Body Disease.
Carla Abdelnour, Christina B Young, Marian Shahid-Besanti, Alena Smith, Edward N Wilson, Geoffrey A Kerchner

Ann Neurol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD).
Anuja Neve, Bibha Das, Jakub Wojtowicz, Zhiyue Huang, Szofia Bullain, Geoffrey A Kerchner

J Alzheimers Dis· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer's disease spectra.
Melanie J Plastini, Carla Abdelnour, Christina B Young, Edward N Wilson, Marian Shahid-Besanti, Geoffrey A Kerchner

Ann Clin Transl Neurol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease.
Gennaro Pagano, Kirsten I Taylor, Judith Anzures Cabrera, Tanya Simuni, Kenneth Marek, Geoffrey A Kerchner

Nat Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson's disease.
Jarod Rutledge, Benoit Lehallier, Pardis Zarifkar, Patricia Moran Losada, Marian Shahid-Besanti, Geoffrey A Kerchner

Acta Neuropathol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of partial volume correction and analysis of longitudinal [F]GTP1 tau PET imaging in Alzheimer's disease using linear mixed-effects models.
Sandra M Sanabria Bohórquez, Suzanne Baker, Paul T Manser, Matteo Tonietto, Christopher Galli, Geoffrey A Kerchner

Front Neuroimaging· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decision making in clinical trials: Interim analyses, innovative design, and biomarkers.
Kathleen A Welsh-Bohmer, Geoffrey A Kerchner, Shobha Dhadda, Miguel Garcia, David S Miller

Alzheimers Dement (N Y)· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a quantitative semi-mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q-ATN model).
Norman A Mazer, Carsten Hofmann, Dominik Lott, Ronald Gieschke, Gregory Klein, Geoffrey A Kerchner

Alzheimers Dement· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
Guoqiao Wang, Yan Li, Chengjie Xiong, Eric McDade, David B Clifford, Geoffrey A Kerchner

Alzheimers Dement (Amst)· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer's disease.
Edward N Wilson, Christina B Young, Javier Ramos Benitez, Michelle S Swarovski, Igor Feinstein, Geoffrey A Kerchner

Alzheimers Res Ther· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial.
Edmond Teng, Paul T Manser, Karen Pickthorn, Flavia Brunstein, Mira Blendstrup, Geoffrey A Kerchner

JAMA Neurol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Gennaro Pagano, Kirsten I Taylor, Judith Anzures-Cabrera, Maddalena Marchesi, Tanya Simuni, Geoffrey A Kerchner

N Engl J Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALS.
Jonathan S Katz, Jeffrey D Rothstein, Merit E Cudkowicz, Angela Genge, Björn Oskarsson, Geoffrey A Kerchner

Ann Clin Transl Neurol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline [F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer's disease.
Edmond Teng, Paul T Manser, Sandra Sanabria Bohorquez, Kristin R Wildsmith, Karen Pickthorn, Geoffrey A Kerchner

Alzheimers Res Ther· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Pharmacokinetics of High-Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy Volunteers.
Michael J Dolton, Aaron Chesterman, Anita Moein, Kaycee M Sink, Ariel Waitz, Geoffrey A Kerchner

Clin Pharmacol Ther· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
Stephen Salloway, Martin Farlow, Eric McDade, David B Clifford, Guoqiao Wang, Geoffrey A Kerchner

Nat Med· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease.
Gai Ayalon, Seung-Hye Lee, Oskar Adolfsson, Corinne Foo-Atkins, Jasvinder K Atwal, Geoffrey A Kerchner

Sci Transl Med· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis